Middle East Pharmaceutical Industries Company (4016.SR) — Cash flow
Operating, investing, and financing cash flow for Middle East Pharmaceutical Industries Company — annual and quarterly.
| Metric (SAR Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | 97↑21.5% | 80↑21.3% | 66↑10.7% | 59↓10.3% | 66 | |
| Depreciation & Amortization | 20↑26.1% | 16↑32.8% | 12↑12.3% | 11↑11.0% | 10 | |
| Deferred Income Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Stock-Based Compensation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Changes in Working Capital | -30↑59.6% | -73↓462.6% | 20↑274.0% | -12↑70.4% | -39 | |
| Accounts Receivable | -41↑29.2% | -58↓2262.4% | -2↓119.3% | 13↑123.2% | -55 | |
| Inventory | -7↑38.3% | -12↓194.0% | 12↑145.5% | -27↓434.4% | 8 | |
| Accounts Payable | 17↑1722.8% | -1↑89.6% | -10↓289.8% | 5↓20.0% | 7 | |
| Other Working Capital | 2↑143.9% | -4↓119.9% | 20↑1045.5% | -2↓551.8% | 0.47 | |
| Other Non-Cash Items | 6↓55.7% | 13↑343.6% | -5↓114.4% | 37↓41.5% | 63 | |
| Net Cash from Operating Activities | 93↑163.8% | 35↓61.9% | 93↑43.3% | 65↑58.8% | 41 | |
| Operating Cash Flow | 93↑163.8% | 35↓61.9% | 93↑43.3% | 65↑58.8% | 41 | |
| Investing Activities | ||||||
| Investment in Property, Plant & Equipment | -34↓208.1% | -11↑46.4% | -21↓1.1% | -21↑16.5% | -25 | |
| Capital Expenditure | -15↓32.4% | -11↑46.4% | -21↓1.1% | -21↑16.5% | -25 | |
| Acquisitions | 0.04↓71.4% | 0.14↑4.4% | 0.14↓66.3% | 0.41↑818.9% | 0.04 | |
| Purchases of Investments | 0.00 | 0.00 | 0.00 | 0.00↑100.0% | -0.17 | |
| Sales & Maturities of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Investing Activities | 0.00↑100.0% | -9↑11.1% | -10↑4.6% | -11↓13.4% | -9 | |
| Net Cash from Investing Activities | -34↓71.5% | -20↑35.0% | -31↓52.6% | -20↑18.5% | -25 | |
| Financing Activities | ||||||
| Net Debt Issuance | 0.08↑101.3% | -6↑0.0% | -6↓33.3% | -5↓119.5% | 24 | |
| Long-Term Net Debt Issuance | 23↑459.5% | -6↑0.0% | -6↓33.3% | -5↓119.5% | 24 | |
| Short-Term Net Debt Issuance | -23↓331.2% | 10 | 0.00 | 0.00 | 0.00 | |
| Net Stock Issuance | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Common Stock Issuance | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Common Stock Issuance | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Share Buybacks | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Preferred Stock Issuance | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividends Paid | -47↓213.2% | -15↑58.3% | -36↑1.0% | -36↑2.3% | -37 | |
| Common Dividends Paid | -47↓213.2% | -15↑58.3% | -36↑1.0% | -36↑2.3% | -37 | |
| Preferred Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Financing Activities | -0.11↓100.8% | 14↑148.3% | -28↓1023.6% | -3 | 0.00 | |
| Net Cash from Financing Activities | -47↓509.2% | -8↑89.1% | -71↓77.7% | -40↓209.6% | -13 | |
| Cash Reconciliation | ||||||
| Effect of Foreign Exchange | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Change in Cash | 12↑55.5% | 8↑186.8% | -9↓282.6% | 5↑52.8% | 3 | |
| Cash at Beginning of Period | 23↑49.9% | 15↓36.5% | 24↑25.0% | 19↑19.5% | 16 | |
| Cash at End of Period | 34↑51.8% | 23↑49.9% | 15↓36.5% | 24↑25.0% | 19 | |
| Income Taxes Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Free Cash Flow | 78↑224.6% | 24↓66.4% | 72↑63.1% | 44↑174.5% | 16 | |
* All figures in Millions of SAR, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.